Company news

Theralase Technologies Inc. (TSXV:TLT) news

Theralase Technologies Inc. news releases on 6ix. Latest, Mar 10, 2025: Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients

Theralase Technologies Inc. (TSXV:TLT) news

Press releases — page 2

Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients

Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma

CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes

Theralase(R) Demonstrates Effective Treatment of Herpes

Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses

Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting

Theralase(R) Launches Three New Clinical Study Sites in USA

Theralase(R) Launches New Clinical Study Site in Canada

Theralase(R) Release's 3Q2024 Financial Statements

Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options

Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer

Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug

Theralase(R) Release's 2Q2024 Financial Statements

Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement

Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy

Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically

Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically

Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)

Rutherrin(R) Increases Efficacy of Chemotherapy

Ruvidar(TM) Enhances Efficacy of Cancer Drug

Theralase(R) Successfully Destroys Lung Cancer

Theralase(R) Technology Effective in Virus Inactivation

Theralase(R) Release's 1Q2024 Financial Statements

Theralase(R) Expands Clinical Team

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement

Theralase(R) Granted Canadian Cancer Vaccine Patent

Theralase(R) Release's 4Q2023 Interim Financial Statements

Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association

24/02/13 - TSX Venture Exchange Stock Maintenance Bulletins

Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease

Theralase Technologies shares update on Phase II Bladder Cancer study

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study

Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA

Theralase Release's 3Q2023 Interim Financial Statements

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement

Theralase(R) Announces Brokered LIFE Financing

Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study

Theralase(R) Files US Patent for Enhanced Immunotherapy

Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)

Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer

Theralase(R) Grants Stock Options

Theralase(R) Closes Private Placement Equity Financing

Theralase Release's 2Q2023 Interim Financial Statements

Theralase(R) Closes Non-Brokered Private Placement Equity Financing

Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

Theralase(R) Announces Appointment of New Independent Director

Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements